Background: Extended-spectrum AmpC (ESAC) b-lactamase enzymes, which are either chromosomally encoded or plasmid encoded, have minor structural changes that broaden their substrate hydrolysis profile. The derepressed AmpC enzyme found once in Enterobacter cloacae CHE was shown to contain a six residue deletion in the H-10 helix in close proximity to the active site. Avibactam is a non-b-lactam inhibitor of Ambler class A, class C and some class D b-lactamases that is in clinical development with several b-lactam agents. It has been shown to inhibit AmpC enzymes, but its microbiological activity against isolates carrying different ESAC enzymes is less well understood.
Introduction
Safe and effective treatment options for infections caused by multidrug-resistant Gram-negative pathogens are decreasing. The use of cephalosporins has been eroded due to the global spread of b-lactamase enzymes that efficiently hydrolyse them and render them ineffective. The novel non-b-lactam b-lactamase inhibitor avibactam inhibits clinically important class A, class C and some class D serine-based b-lactamases and is being developed in combination with ceftazidime, ceftaroline fosamil and aztreonam. Whereas inhibitors of class A b-lactamases, such as clavulanic acid, tazobactam and sulbactam, have been used clinically, there is currently no inhibitor of class C b-lactamases that is approved for clinical use. The combination of avibactam with ceftazidime, ceftaroline or aztreonam in in vitro susceptibility testing has been shown to be effective against a wide range of Gram-negative pathogens, including those species that have a chromosomal class C b-lactamase that is inducible and can become stably hyperexpressed upon mutation. 1 -3 Enterobacter cloacae is a nosocomial pathogen that has been associated with a range of infections such as intra-abdominal, urinary tract and respiratory infections as well as bacteraemia. The chromosomally encoded b-lactamase found in E. cloacae can often become derepressed during treatment causing resistance to b-lactam drugs. Extended-spectrum AmpC (ESAC) cephalosporinases are enzymes that have been reported in several Enterobacteriaceae spp. and, although not common, are characterized by possessing a broader substrate profile that includes the fourth-generation cephalosporins cefepime and cefpirome. 4 The predominant areas for mutations that result in the ESAC phenotype are the R1 binding site or near the R2 binding site of cephalosporins. 5 Recent data on several ESAC R2 variants suggest that avibactam remains active against these enzymes as the variations are not in close proximity to 6 However, there is a particular R2 modification that generates an ESAC phenotype that has only been observed once, in the E. cloacae CHE strain. This strain was isolated in 1998 from stools of a neutropenic paediatric patient who had been on long-term treatment with cefepime and had changes in residues that are closer to the avibactam binding pocket. 7 This isolate was fully resistant to a range of b-lactam agents including cefepime and was reported to contain an overexpressed ESAC enzyme that carried a six amino acid residue deletion. Here, we tested the ability of avibactam to inhibit this R2 binding site variant of an ESAC b-lactamase.
Materials and methods
Bacterial strains and susceptibility testing E. cloacae CHE and 293HT6 (contains the P99 AmpC sequence) were part of the AstraZeneca culture collection. E. cloacae isolate ARC3601 that contains the NDM-1 metallo-b-lactamase was obtained from CDC (Atlanta, GA, USA). The ARC3963 (USA) and ARC4438 (Canada) E. cloacae isolates were obtained from International Health Management Associates (Schaumburg, IL, USA). The MIC for each isolate was determined using the broth microdilution method following CLSI guidelines. All compounds and reference standards were tested in accordance with CLSI recommendations. 8 Escherichia coli ATCC 25922 and Klebsiella pneumoniae ATCC 700603 were used as quality control isolates. The active component of ceftaroline fosamil, ceftaroline, was used in all in vitro susceptibility testing and was obtained from Cerexa, Inc. (Oakland, CA, USA). Cefpodoxime was obtained from Toku-E Company (Bellingham, WA, USA) and all other reference compounds used were obtained from US Pharmacopeial Convention (Rockville, MD, USA).
Whole genome sequencing and analysis
Genomic DNA purified on the Maxwell 16 w platform (Promega, Madison, WI, USA) and quantified using the Qubit w fluorimeter (Invitrogen Life Technologies, Grand Island, NY, USA) was used as input material for library construction. DNA libraries were prepared using the Nextera library construction protocol (Illumina, San Diego, CA, USA) following the manufacturer's instructions and sequenced on a MiSeq Sequencer (Illumina). For each isolate, 2.5 million 150 bp paired-end sequence reads were de novo assembled and analysed using the CLC bio (Cambridge, MA, USA) suite of software tools.
Quantification of mRNA levels
RNA from mid-logarithmically grown E. cloacae strains was prepared using the Maxwell 16 w LEV simplyRNA purification kit from Promega (Fitchburg, WI, USA). A total of 5 ng of RNA was used in an RT-PCR assay using the Qiagen Quantitect SYBR Green RT-PCR kit (Germantown, MD, USA) and a Bio-Rad CFX96 TM instrument. The oligonucleotides used to detect the expression of the chromosomal bla ampC allele in E. cloacae were 5
′ -GCATGGCGGTGGCCGTTAT-3 ′ and 5 ′ -CTGCTTGCCCGTCAGCTGT-3 ′ and the control oligonucleotides to detect the expression of the rpsL ribosomal gene were 5 ′ -GTGTATACCACCACTCCT-3 ′ and 5 ′ -TCTTTAACACGACCGCCA-3 ′ . The level of rpsL expression was used for normalization and the relative quantification of ampC expression was performed using a comparative Ct method.
Molecular modelling
Several protein structure coordinates obtained from the Protein Data Bank (PDB) were used for the structural hypotheses presented. The structure of avibactam in complex with AmpC from Pseudomonas aeruginosa (PDB: 4HEF) was overlaid with the AmpC apoenzyme structure from E. cloacae P99 (PDB: 1XX2) to understand the binding mode of avibactam. The binding modes of ceftazidime and aztreonam to AmpC were obtained from PDB structures 1IEL and 1FR6, respectively. Structural overlays and visualization were performed using Pymol (Schrö dinger, www.pymol.org).
Results and discussion

Structural analysis
There are a number of different small structural modifications in class C b-lactamases that result in enzymatic activity against extended-spectrum cephalosporinases by either improved substrate binding or faster catalysis. 5 Some of these changes influence the R2 binding pocket of cephalosporins while others influence the R1 binding pocket. Compared with the cephalosporin molecules, avibactam is much smaller in size and thus does not interact with all of the cephalosporin-binding residues, including those interactions with the core cephem ring and with the oxyimino side chain. However, the residues that are involved in avibactam binding are critical for the potency of this inhibitor and, as such, any significant alteration in these residues would be predicted to have an impact on the inhibitory capacity. Avibactam has recently been shown to efficiently inhibit some ESAC enzyme variants when used in combination with ceftazidime and cefepime. 6 However, the CHE enzyme encoded by an E. cloacae isolate identified in 1998 is unique among the documented ESAC enzymes, as it contains a structural modification that is adjacent to the avibactam binding pocket. This enzyme contains a six amino acid deletion in the H-10 helix (residues 289 -294, SKVALA) in the R2 binding pocket (Figure 1) . The H-10 helix deletion is thought to widen the R2 binding pocket, which results in better accommodation of the large R2 group of thirdgeneration cephalosporins such as ceftazidime, as reflected by its 20-fold improved affinity for ceftazidime compared with the P99 AmpC enzyme (1 mM for CHE compared with 20 mM for P99 7 ) and elevated MIC values (Table 1 ). This improvement in affinity is less for aztreonam, which does not contain a large group in the R2 position, and the hydrolysis rate, and hence MIC value, would be similar for isolates containing either the native or CHE ESAC variant ( Table 1) . Analysis of the avibactam binding pocket based on the structure of P. aeruginosa AmpC in complex with avibactam shows that the H-10 helix region forms a part of the sulphate binding site of the covalently bound inhibitor. 9 While none of the six amino acids that are deleted in the E. cloacae CHE AmpC variant make a specific interaction with avibactam, in the wild-type AmpC enzyme they form a hydrophobic surface that allows the sulphate moiety to be positioned correctly for an optimal interaction with Lys315 and Thr316 of the KTG motif and Asn346 from helix H-11 (Figure 2) . The difference caused by this deletion has a benefit for cephalosporin binding, but there does not appear to be any benefit for avibactam, rather a predicted negative impact on its affinity. Thus, this structural change may be expected to reduce, but not abolish, the binding potency of avibactam.
Genome sequencing and expression analysis
To test this structural hypothesis, E. cloacae CHE and several other E. cloacae isolates were characterized. De novo assembly of the sequence reads and similarity searches against a database of b-lactamase enzymes confirmed that strains ARC3963, ARC4438, CHE and 293HT6 contained only the chromosomal Avibactam activity against ESAC b-lactamases 2943 JAC class C (ampC) allele. E. cloacae isolate ARC3601 was included as a negative control strain and contained, in addition to the chromosomal ampC allele, genes that encoded three class A (TEM-1, CTX-M-15 and LAP-2) b-lactamase enzymes, two class D (OXA-1 and OXA-9) b-lactamase enzymes and one class B (NDM-1) b-lactamase enzyme.
Alignment of the AmpC proteins from the five E. cloacae isolates confirmed the six residue deletion observed in the CHE isolate, which also contained four other amino acid substitutions compared with the P99 enzyme found in strain 293HT6. The other isolates contained between 3 and 12 amino acid differences relative to P99 (Figure 3) , which is consistent with the greater diversity observed in the chromosomal AmpC proteins of this species when compared with P. aeruginosa, which also carries a chromosomal bla ampC allele (S. D. Lahiri, unpublished results). However, the eight key residues that directly interact with avibactam upon binding and acylation of the inhibitor 9 were absolutely conserved between all five AmpC enzymes (Figure 3) .
The relative level of bla ampC expression in each E. cloacae isolate was determined by RT-PCR normalized as a ratio to the wellexpressed ribosomal subunit gene rpsL. Strain ARC3963 had a low level of bla ampC expression, which was supported by MIC values of 1 -2 mg/L of the various cephalosporins (Table 1) . Although isolate ARC3601 also had a fully repressed bla ampC , a high level of b-lactam resistance was mediated by the other six b-lactamases contained in this isolate. The three remaining E. cloacae isolates had derepressed bla ampC alleles and high levels of expression. Using the average bla ampC expression level of the ceftazidimesusceptible isolate ARC3963 along with three other ceftazidimesusceptible isolates (data not shown) as a baseline, the level of bla ampC expression ranged from 416-fold in 293HT6 up to 3539-fold in ARC4438. The level of expression in E. cloacae CHE was 1910-fold over this baseline (Table 1) .
Susceptibility studies
The ability of avibactam to inhibit the E. cloacae CHE ESAC enzyme was investigated. The MIC of ceftazidime (.512 mg/L) was reduced ≥16-fold in the presence of the standard 4 mg/L avibactam and similar magnitudes of restoration were observed when avibactam was tested in combination with ceftaroline ( Table 1) . The MIC value of aztreonam, a monobactam known to be hydrolysed less effectively by class C b-lactamases, for E. cloacae CHE was 64 mg/L and this was reduced 32-fold when tested in combination with 4 mg/L avibactam (Table 1) . To eliminate the possibility that the high level of expression of the ESAC enzyme was responsible for the incomplete inhibition by avibactam, additional clinical E. cloacae isolates with high ampC expression levels, including one that had a higher level of expression than CHE, were also tested ( Table 1 ). The ARC4438 isolate had the highest level of ampC expression and, while susceptible to cefepime, was fully resistant to the other b-lactam drugs. However, when tested in combination with 4 mg/L avibactam, the ceftazidime and ceftaroline MIC values were each reduced 256-fold, from 256 to 1 mg/L for ceftazidime and from 128 to 0.5 mg/L for ceftaroline ( Table 1 ), demonstrating that this amount of avibactam was sufficient to inhibit the large amount of AmpC being produced.
Susceptibility testing was also performed in combination with increasing concentrations of avibactam to confirm the hypothesis that the inhibitory capacity of avibactam was only partially diminished. Higher levels of avibactam decreased the MIC values for all isolates in a dose-dependent manner. This included E. cloacae Figure 1 . Representation of the location of the six amino acid residues (brown; SKVALA) that are deleted in the E. cloacae CHE isolate in the context of the ceftazidime (cyan), aztreonam (green) and avibactam (yellow) binding modes. The structure shown here is an overlay of the P. aeruginosa AmpC-avibactam co-crystal structure (PDB: 4HEF) on the AmpC apoenzyme structure from E. cloacae P99 (PDB: 1XX2).
Lahiri et al. (Table 1) . As 16 mg/L is well below the intrinsic activity of avibactam in this isolate (MIC ¼ 256 mg/L), this, together with the partial restoration observed with the 4 mg/L combinations, strongly supports the structural hypothesis that avibactam can inhibit the ESAC variant contained in the CHE strain, but does so with less efficiency. To compare the observation that increasing concentrations of avibactam can fully inhibit the ESAC enzyme and contrast it with a b-lactamase enzyme that cannot be inhibited by avibactam, a metallo-b-lactamasecontaining E. cloacae isolate was included in the analysis as a negative control. As expected, E. cloacae isolate ARC3601, which contained the metallo-b-lactamase NDM-1 along with many other class A, class C and class D b-lactamases, remained fully resistant to the ceftazidime and ceftaroline combinations, even with high levels of avibactam. However, it should be noted that in combination with aztreonam, which is not hydrolysed by NDM-1, the addition of avibactam at all levels could fully inhibit the remaining b-lactamase enzymes in this isolate and reduce the MIC to ≤0.5 mg/L (Table 1) . values, representing the relative quantification of ampC expression using rpsL expression as the internal control using the comparative Ct method, for these four isolates ranged from 0.013 to 0.027 units. 
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Conclusions
The ESAC structural modification in E. cloacae CHE has only been reported in one clinical isolate 15 years ago in a paediatric patient and analysis of the AmpC b-lactamase from .100 additional E. cloacae isolates has confirmed the rarity of this variation (S. D. Lahiri, unpublished results). While the overall sequence variation of E. cloacae AmpC proteins is quite significant ( 40% of residues vary in at least one isolate), the absolute conservation of the key avibactam-binding residues to date among these proteins combined with the very high overall conservation of other chromosomally encoded and plasmidic class C enzymes suggests that avibactam will efficiently inhibit the vast majority of class C b-lactamases (S. D. Lahiri, unpublished results). However, a small number of structural variants of class C b-lactamases have been observed and it is important to understand the ability of avibactam to inhibit these enzymes. While it has been previously demonstrated that avibactam can effectively inhibit many of the reported ESAC enzyme variations, 6 the work described here suggests that not all of the extended-spectrum class C b-lactamase enzymes are susceptible to inhibition to an equivalent extent. Certain ESAC variations that are close to the avibactam binding site do impair the activity of this inhibitor. However, this weaker inhibition is only observed in the background of improved substrate hydrolysis and as such bacteria remain susceptible to a combination of avibactam with a weaker substrate such as aztreonam.
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